Valuation: Mendus AB

Market Cap 442M 46.25M 40.17M 37.31M 34.4M 64.81M 4.42B 65.98M 173M 2.19B 174M 170M 7.37B P/E 2026 *
-4.58x
P/E 2027 * -5.96x
Enterprise Value 120M 12.6M 10.95M 10.17M 9.38M 17.66M 1.2B 17.98M 47.12M 598M 47.33M 46.29M 2.01B EV / Sales 2026 *
20.2x
EV / Sales 2027 * 1.63x
Free-Float
34.33%
Yield 2026 *
-
Yield 2027 * -
1 day+0.14%
1 week+2.67%
Current month+19.69%
1 month+19.69%
3 months+35.09%
6 months+19.48%
Current year+23.75%
1 week 6.47
Extreme 6.47
6.94
1 month 5.63
Extreme 5.63
7.24
Current year 3.86
Extreme 3.86
7.49
1 year 3.86
Extreme 3.86
10
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 16/03/2021
Chief Executive Officer 76 13/12/2019
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
28/2/22 Buy

Chief Technology Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
24/2/22 Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%+2.67%-24.10%-31.52% 43.78M
-0.80%+5.16%-0.70%+13.00% 48.95B
-3.95%+14.70%+24.15%+5.15% 40.75B
+6.22%+1.81%+419.17%+647.45% 38.46B
-1.57%-1.44%+7.38%+43.06% 36.38B
+5.56%+11.70%+11.64%+51.50% 28.45B
-0.39%-0.63% - - 16.62B
-1.13%-4.54%+32.10%+126.95% 16.33B
-7.10%-2.81%-8.80%-34.35% 13.65B
-0.06%+3.75%+3.81%+10.08% 13.56B
Average -0.31%+6.10%+51.63%+92.37% 25.32B
Weighted average by Cap. +0.07%+7.20%+76.62%+129.01%

Financials

2026 *2027 *
Net sales 5.97M 625K 543K 504K 465K 876K 59.65M 891K 2.34M 29.63M 2.35M 2.3M 99.63M 150M 15.67M 13.61M 12.64M 11.66M 21.96M 1.5B 22.36M 58.6M 743M 58.86M 57.57M 2.5B
Net income -150M -15.73M -13.66M -12.68M -11.7M -22.04M -1.5B -22.44M -58.8M -746M -59.06M -57.76M -2.51B -66.57M -6.97M -6.05M -5.62M -5.19M -9.77M -666M -9.94M -26.06M -331M -26.18M -25.6M -1.11B
Net Debt -321M -33.65M -29.23M -27.14M -25.03M -47.15M -3.21B -48M -126M -1.6B -126M -124M -5.37B -197M -20.63M -17.92M -16.64M -15.35M -28.91M -1.97B -29.43M -77.14M -978M -77.47M -75.78M -3.29B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
30/07/26 SEK 6.930 +0.14% 13,828
29/07/26 SEK 6.920 +0.44% 11,490
28/07/26 SEK 6.890 +4.24% 41,897
27/07/26 SEK 6.610 +1.54% 18,291
24/07/26 SEK 6.510 -3.56% 24,416
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.930SEK
Average target price
33.00SEK
Spread / Average Target
+376.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock